A Study to Evaluate the Safety and Immunogenicity of Seasonal Influenza Vaccine and an Adenovirus Serotype 26- Based Vaccine Encoding for the Respiratory Syncytial Virus Pre-fusion F Protein (Ad26.RSV.preF), With and Without Co-administration, in Adults Aged 60 Years and Older in Stable Health

NCT03339713 | Completed Phase 2 Results FDA Drug

• 2 other identifiers: CR108403VAC18193RSV2003
• Study Type: interventional
• Target: 180
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to demonstrate the non-inferiority of the concomitant administration of an adenovirus serotype 26- based vaccine encoding for the respiratory syncytial virus pre-fusion F protein (Ad26.RSV.preF) and seasonal influenza vaccine versus the administration of seasonal influenza vaccine alone in terms of humoral immune response expressed by the geometric mean titers (GMTs) of hemagglutination inhibition (HI) antibody titers against all four influenza vaccine strains 28 days after the administration of influenza vaccine, and to assess the safety and tolerability of a single dose of 1\*10\^11 viral particles (vp) of Ad26.RSV.preF, administered intramuscularly to participants aged greater than or equal to 60 years separately or concomitantly with seasonal influenza vaccine.

Conditions

Healthy

Outcome Measures

Primary Outcomes (7)

• Hemagglutination Inhibition (HI) Antibody Titers as Measured by Hemagglutination Inhibition Assay (HAI) Against Each of the Four Vaccine Influenza Strains

  Humoral immune responses expressed by the geometric mean titers (GMTs) of HI antibody titers against each of four influenza vaccine strains (A/Michigan, A/Hong Kong, B/Brisbane and B/Phuket). Serum specimens were tested for the presence of HAI antibodies to influenza vaccine strains. The HAI assay was conducted using serum samples from participants.

  28 days after vaccination (Day 29)

• Post-dose 1: Percentage of Participants Reporting at Least 1 Solicited Local and Systemic Adverse Events (AEs)

  Percentage of participants reporting at least 1 solicited local and systemic AEs were shown. Solicited local AEs: erythema, swelling/induration, and pain/tenderness. Solicited systemic AEs: fatigue, headache, myalgia, arthralgia, chills, nausea and fever. An AE is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with a clear causal relationship with the relevant investigational product.

  Up to 7 days post-dose 1 on Day 1 (Day 8)

• Post-dose 2: Percentage of Participants Reporting at Least 1 Solicited Local and Systemic AEs

  Percentage of participants reporting at least 1 solicited local and systemic AEs were shown. Solicited local AEs: erythema, swelling/induration, and pain/tenderness. Solicited systemic AEs: fatigue, headache, myalgia, arthralgia, chills, nausea and fever. An AE is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with a clear causal relationship with the relevant investigational product.

  Up to 7 days post-dose 2 on Day 29 (Day 36)

• Post-dose 1: Percentage of Participants With Unsolicited AEs

  Percentage of participants with unsolicited AEs were shown. Unsolicited AEs are all AEs for which participants were specifically not questioned in the participant diary. An AE is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with a clear causal relationship with the relevant investigational product.

  Up to 28 days post-dose 1 on Day 1 (Day 29)

• Post-dose 2: Percentage of Participants With Unsolicited AEs

  Percentage of participants with unsolicited AEs 2 were shown. Unsolicited AEs are all AEs for which participants were specifically not questioned in the participant diary. An AE is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with a clear causal relationship with the relevant investigational product.

  Up to 28 days post-dose 2 on Day 29 (Day 57)

• Post-dose 1: Percentage of Participants With Serious Adverse Events (SAEs)

  A SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.

  Up to 6 months post-dose 1 (Day 183)

• Post-dose 2: Percentage of Participants With SAEs

  A SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.

  Up to 6 months post-dose 2 (Day 211)

Secondary Outcomes (3)

• Respiratory Syncytial Virus (RSV) A2 Strain Neutralization Antibody Titers

  Baseline and Day 29 (post Ad26.RSV.preF)

• RSV Fusion Protein (F-protein) Geometric Mean Titers (GMTs) as Assessed by Enzyme-linked Immunosorbent Assay (ELISA)- Pre-Fusion

  Baseline and Day 29 (post Ad26.RSV.preF)

• RSV Fusion Protein (F-protein) GMTs as Assessed by ELISA- Post-Fusion

  Baseline and Day 29 (post Ad26.RSV.preF)

Study Arms (2)

Ad26.RSV.preF Plus Fluarix Then Placebo: Group 1

EXPERIMENTAL

Participants will receive intramuscular injection of 1\*10\^11 viral particles (vp) of an adenovirus serotype 26- based vaccine encoding for the respiratory syncytial virus pre-fusion F protein (Ad26.RSV.preF) on 1 arm administered at the same time as a commercially available seasonal influenza vaccine (Fluarix) on the other arm at Day 1, and intramuscular injection of placebo on Day 29.

Biological: Ad26.RSV.preF; Biological: Fluarix; Biological: Placebo

Placebo Plus Fluarix Then Ad26.RSV.preF: Group 2

EXPERIMENTAL

Participants will receive intramuscular injection of placebo administered at the same time as a commercially available seasonal influenza vaccine (Fluarix) on Day 1, and 1\*10\^11 vp of Ad26.RSV.preF on Day 29.

Biological: Ad26.RSV.preF; Biological: Fluarix; Biological: Placebo

Interventions

Ad26.RSV.preF BIOLOGICAL

Ad26.RSV.preF will be administered as intramuscular injection at a dose of 1\*10\^11 vp.

Also known as: JNJ-64400141

Ad26.RSV.preF Plus Fluarix Then Placebo: Group 1; Placebo Plus Fluarix Then Ad26.RSV.preF: Group 2

Fluarix BIOLOGICAL

Fluarix will be administered as intramuscular injection.

Ad26.RSV.preF Plus Fluarix Then Placebo: Group 1; Placebo Plus Fluarix Then Ad26.RSV.preF: Group 2

Placebo BIOLOGICAL

Placebo will be administered as intramuscular injection of sterile 0.9 percent (%) saline for injection.

Ad26.RSV.preF Plus Fluarix Then Placebo: Group 1; Placebo Plus Fluarix Then Ad26.RSV.preF: Group 2

Eligibility Criteria

• Age: 60 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Each participant must sign an informed consent form (ICF) indicating that he or she understands the purpose of and procedures required for the study, is willing to participate in the study and attend all scheduled visits, and is willing and able to comply with all study procedures and adhere to the prohibitions and restrictions specified in this protocol
• Before randomization, a woman must be:
• Postmenopausal (A postmenopausal state is defined as no menses for 12 months without an alternative medical cause) and
• Not intending to conceive by any methods
• In the investigator's clinical judgment, participant must be either in good or stable health, and not at risk of serious complications from influenza. Participants may have underlying illnesses such as hypertension, type 2 diabetes, hyperlipoproteinemia, or hypothyroidism, as long as their symptoms/signs are medically controlled. If they are on medication for a condition, the medication dose must have been stable for at least 12 weeks (or only small, clinically non-significant changes have been made in the judgement of the Principal Investigator) preceding vaccination and expected to remain stable for the duration of the study. Participants will be included on the basis of physical examination, medical history, vital signs, and 12-lead electrocardiogram (ECG) performed on Day 1
• From the time of first vaccination through 3 months after the second dose of study vaccine, participant agrees not to donate blood
• Participant must be willing to provide verifiable identification, have means to be contacted and to contact the investigator during the study

You may not qualify if:

• Participant has acute illness (this does not include minor illnesses such as diarrhea) or temperature greater than or equal to (\>=) 38.0 degree Celsius (ºC) within 24 hours prior to the first dose of study vaccine; enrollment at a later date is permitted
• Participant has a serious chronic disorder, including severe chronic obstructive pulmonary disease or clinically significant congestive heart failure, requirement for supplemental oxygen, end stage renal disease with or without dialysis, clinically unstable cardiac disease, Alzheimer's disease, or has any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant (for example, compromise well-being) or that could prevent, limit, or confound the protocol-specified assessments
• Participant has history of malignancy within 5 years before screening (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or malignancy, which is considered cured with minimal risk of recurrence)
• Participant has had major surgery (per the investigator's judgment), within 4 weeks before dosing, or will not have fully recovered from surgery, or has surgery planned during the time the participant is expected to participate in the study or within 6 months after the final dose of study vaccine
• Participant has chronic active hepatitis B or hepatitis C infection, documented by hepatitis B surface antigen and hepatitis C antibody, respectively

Sponsors & Collaborators

• Janssen Vaccines & Prevention B.V.: lead

Study Sites (1)

Coastal Carolina Research Center

Mt. Pleasant, South Carolina, 29464, United States

Location

Related Publications (1)

• Sadoff J, De Paepe E, Haazen W, Omoruyi E, Bastian AR, Comeaux C, Heijnen E, Strout C, Schuitemaker H, Callendret B. Safety and Immunogenicity of the Ad26.RSV.preF Investigational Vaccine Coadministered With an Influenza Vaccine in Older Adults. J Infect Dis. 2021 Feb 24;223(4):699-708. doi: 10.1093/infdis/jiaa409.

  PMID: 32851411 DERIVED

MeSH Terms

Interventions

fluarix

Limitations and Caveats

Although qualification of the site was satisfactory for peripheral blood mononuclear cells (PBMC) processing,during the study PBMC processing resulted in much lower yield than expected, which have affected the quality of PBMC. While sample quality requirements on sample viability were met for most samples,viability was considered lower than commonly expected.An indication of possible suboptimal quality of PBMC samples were also be a low baseline responses observed in comparison to other studies.

Results Point of Contact

• Title: Clinical Franchise Leader
• Organization: Janssen Research & Development, LLC

ClinicalTrialDisclosure@its.jnj.com

844-434-4210

Study Officials

• Janssen Vaccines & Prevention B.V. Clinical Trial

  Janssen Vaccines & Prevention B.V.

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 8, 2017
• First Posted: November 13, 2017
• Study Start: December 7, 2017
• Primary Completion: July 23, 2018
• Study Completion: July 23, 2018
• Last Updated: February 4, 2025
• Results First Posted: August 18, 2021

Record last verified: 2025-01

Locations

US (1)